||Last Updated: Nov 17th, 2006 - 22:35:04
Ramelteon shows less potential to foster abuse and dependence
As part of the effort to develop effective behavioral and medical sleep therapies, scientists consider the potential for dependence and abuse associated with prescription sleep drugs. This line of research has produced findings showing that a recently approved prescription sleep drug may spare users the potential for dependence and abuse found with other sleep aids. Laboratory studies of the effects of ramelteon suggest that the drug's targeting of the brain's melatonin receptors rather than its benzodiazepine receptors make its subjective side effects different from those of old and new sedative hypnotics.
Jun 5, 2006, 16:19
Ramelteon showed significant reduction in time to fall asleep
Results of a sub-analysis from a Phase III clinical study showed that ROZEREMTM (ramelteon) significantly reduced time to fall asleep in adults with chronic insomnia and showed no evidence of rebound insomnia or withdrawal effects. The results were presented today at the 2006 Annual Meeting of the American Academy of Neurology.
Apr 3, 2006, 23:35
CX717 Reverses Effects of Sleep Deprivation on Brain
Research in monkeys suggests that a new drug can temporarily improve performance and reverse the effects of sleep deprivation on the brain, which would be a breakthrough in helping shift workers, health professionals, military personnel and others who must function at top performance in spite of sleep deficits.
Aug 24, 2005, 04:15
Approval for Clonazepam Orally Disintegrating Tablets
Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market Clonazepam Orally Disintegrating Tablets, 0.125 mg, 0.25 mg, 0.5 mg, 1 mg & 2 mg, the generic equivalent of Hoffman La Roche's Klonopin(R) Wafers. The Company plans to launch its product immediately.
Aug 11, 2005, 22:58
NDA accepted to review Indiplon for the treatment of insomnia
Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for indiplon tablets for review for the treatment of insomnia in both adult and elderly patients.
Jul 27, 2005, 13:44
FDA Approves Ramelteon, the First 'No Abuse' Drug for Insomnia
Takeda Pharmaceuticals North America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ROZEREM(TM) (ramelteon) 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset. The FDA approval allows physicians to prescribe ROZEREM for long-term use in adults.
Jul 23, 2005, 23:56
FDA approved Ramelteon
Takeda Pharmaceuticals North America, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ROZEREMTM (ramelteon) 8-mg tablets for the treatment of insomnia characterized by difficulty with sleep onset. The FDA approval allows physicians to prescribe ROZEREM for long-term use in adults.
Jul 23, 2005, 18:12
Older adults falling asleep faster with Ramelteon
Results from a Phase 3 clinical study presented at the 2005 Annual Scientific Meeting of the American Geriatrics Society showed that bedtime administration of ramelteon, an investigational compound currently under review for the treatment of insomnia, significantly reduced time to fall asleep in older adults with chronic insomnia. Additionally, no rebound insomnia or withdrawal effects were observed.
May 13, 2005, 16:54